News

The settlement effectively ends the lawsuit involving a challenge by Glenmark which sought to launch a generic version of Zetia before the April 2017 expiration of the patent

MAP Pharmaceuticals confirmed with the FDA that four clinical trials, which already were included in the company’s operating budget, are required to support a new drug application (NDA)

Crucell is developing the malaria vaccine vector in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, the Centre National de Recherche

Ferring Pharmaceuticals will initially market Lysteda in the US, and is evaluating opportunities in other markets. Lysteda oral tablets received approval on November 13, 2009 following a priority

Mr Weis said that abnormal signaling contributes to many diseases such as cancer and diabetes, so the method can be used to develop new drugs for the diseases.

CLC bio said that its high-throughput sequence analysis infrastructure is expected to empower both OSC’s scientists and OSC’s Genome Network Analysis Service (GeNAS) with a user-friendly and fast

Soligenix said that the new patent’s main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower

The recommendations are patient centered, and were developed following a call for such standards by the Institute of Medicine (IOM) on the issue of health literacy. The recommendations

BD Biosciences said that the system’s modular architecture along with exchangeable detector options, hands-on controls, and sorting options make it adaptable to a wide variety of site and